NZ749389A - Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement - Google Patents

Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Info

Publication number
NZ749389A
NZ749389A NZ749389A NZ74938917A NZ749389A NZ 749389 A NZ749389 A NZ 749389A NZ 749389 A NZ749389 A NZ 749389A NZ 74938917 A NZ74938917 A NZ 74938917A NZ 749389 A NZ749389 A NZ 749389A
Authority
NZ
New Zealand
Prior art keywords
diseases
optic
lipids
prevention
retinal
Prior art date
Application number
NZ749389A
Other languages
English (en)
Inventor
Yuhong Dong
Chun-Hsiung Chang
Shengtang Lin
Original Assignee
Sunregen Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunregen Healthcare Ag filed Critical Sunregen Healthcare Ag
Publication of NZ749389A publication Critical patent/NZ749389A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
NZ749389A 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement NZ749389A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347103P 2016-06-08 2016-06-08
PCT/CN2017/087341 WO2017211274A1 (en) 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Publications (1)

Publication Number Publication Date
NZ749389A true NZ749389A (en) 2022-12-23

Family

ID=60577583

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ749389A NZ749389A (en) 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Country Status (12)

Country Link
US (2) US11406616B2 (OSRAM)
EP (1) EP3468551A4 (OSRAM)
JP (2) JP6872805B2 (OSRAM)
KR (1) KR20190017873A (OSRAM)
CN (2) CN110300581B (OSRAM)
AU (1) AU2017277005B2 (OSRAM)
CL (1) CL2018003537A1 (OSRAM)
MX (1) MX2018015188A (OSRAM)
NZ (1) NZ749389A (OSRAM)
SG (1) SG11201810580PA (OSRAM)
TW (1) TWI749016B (OSRAM)
WO (1) WO2017211274A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
CN111773351A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用
CN111773274A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用
US12485103B2 (en) * 2019-11-27 2025-12-02 Refine Holdings Co., Ltd. Insulin secretion-promoting agent and blood sugar level improver using same, diabetes improver, and food
KR20240022560A (ko) * 2021-06-18 2024-02-20 썬리겐 헬쓰케어 아게 바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물
JP2023061448A (ja) * 2021-10-20 2023-05-02 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
WO2024075625A1 (ja) * 2022-10-02 2024-04-11 リファインホールディングス株式会社 視野欠損障害、光誘発眼組織障害およびその関連障害の予防剤、進行防止剤、改善剤、並びに食品

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558351A (en) 1978-07-05 1980-01-21 Hitachi Ltd Press machine
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
JPS5919775U (ja) 1982-07-26 1984-02-06 ワイケイケイ株式会社 カ−テンウオ−ルの断熱窓
JPH02247125A (ja) 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
JP3558351B2 (ja) 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
DE19821003A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2319508A1 (en) 2000-05-01 2011-05-11 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
AU2001264079A1 (en) 2000-06-14 2001-12-24 William Leslie Porter Lipids for modulating immune response
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
WO2002083120A2 (en) 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CN1764446A (zh) * 2003-03-13 2006-04-26 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
WO2004103307A2 (en) * 2003-05-20 2004-12-02 Baylor Research Institute Method of use of five and fifteen carbon fatty acids
JP4334956B2 (ja) * 2003-09-18 2009-09-30 株式会社ノエビア 細胞賦活剤、美白剤、及び抗酸化剤
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
NZ575655A (en) 2006-09-26 2012-06-29 Baylor Res Inst Nutrient sensor
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
KR100829729B1 (ko) 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
CA2704286C (en) 2007-11-02 2016-08-23 Prometic Biosciences Inc. Medium-chain length fatty acids and glycerides as nephroprotection agents
DE102008046227A1 (de) * 2008-06-10 2009-12-17 Ludwig-Maximilians-Universität München Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden
DE102008057867A1 (de) 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN101879156B (zh) 2009-05-07 2013-01-30 上海医药工业研究院 一种药物组合物及其应用
MX348036B (es) 2009-12-30 2017-05-24 Baylor Res Institute Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido.
AR080357A1 (es) * 2010-01-08 2012-04-04 Catabasis Pharmaceuticals Inc Derivados de fumaratos de acidos grasos, composiciones farmaceuticas y sus usos
CN102883733B (zh) * 2010-02-10 2014-08-13 奥力榨油化株式会社 Age生成抑制剂
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
KR20130041902A (ko) 2010-06-14 2013-04-25 베일러 리서치 인스티튜트 성인 폴리글루코산체병（ａｐｂｄ）의 치료를 위한 트리헵타노인 식이
CN103096877B (zh) * 2010-07-15 2017-09-22 海布里詹尼克斯股份公司 维生素d的14‑差向异构‑类似物的新型制剂
JP5810166B2 (ja) 2011-08-26 2015-11-11 国立大学法人大阪大学 糖尿病性心血管合併症の予防・治療剤
CN102526643B (zh) * 2012-03-22 2013-09-11 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
MX373650B (es) 2012-12-13 2020-03-31 Baylor Res Institute At Dallas Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1.
WO2015014497A1 (en) * 2013-08-02 2015-02-05 Schweitzer-Mauduit International, Inc. Edible product comprising reconstituted plant material
US9833430B2 (en) 2013-11-14 2017-12-05 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
CN103641713B (zh) * 2013-11-15 2015-10-21 浙江大学 甘油单酯衍生物的制备方法及应用
WO2015110977A1 (en) 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
JP6406978B2 (ja) 2014-11-04 2018-10-17 株式会社シー・アクト 脂肪酸混合物
CN105267501A (zh) * 2015-11-04 2016-01-27 夏茂森 一种治疗毒蛇咬伤的中药组合物
CN105381182A (zh) 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用
CN108289873A (zh) 2015-12-04 2018-07-17 雀巢产品技术援助有限公司 用于改善认知的方法

Also Published As

Publication number Publication date
SG11201810580PA (en) 2018-12-28
JP6872805B2 (ja) 2021-05-19
KR20190017873A (ko) 2019-02-20
CL2018003537A1 (es) 2019-05-03
CN117298092A (zh) 2023-12-29
US20190255129A1 (en) 2019-08-22
WO2017211274A1 (en) 2017-12-14
CN110300581B (zh) 2023-09-08
JP2019518034A (ja) 2019-06-27
US20220362197A1 (en) 2022-11-17
AU2017277005A1 (en) 2019-01-17
US11406616B2 (en) 2022-08-09
MX2018015188A (es) 2019-08-21
TWI749016B (zh) 2021-12-11
EP3468551A1 (en) 2019-04-17
TW201801720A (zh) 2018-01-16
CA3026152A1 (en) 2017-12-14
JP2021113204A (ja) 2021-08-05
CN110300581A (zh) 2019-10-01
EP3468551A4 (en) 2020-01-22
AU2017277005B2 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
NZ749389A (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP2013545730A5 (OSRAM)
CA2909160C (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
IL189032A (en) Small compounds that correct incorrect folding of protein and their use
CN113164420B (zh) 治疗组合物
JP2019518034A5 (OSRAM)
MX2023012723A (es) Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
JP5009451B1 (ja) 抗がん剤による末梢神経障害の予防又は治療剤
EP2144887A1 (en) Dosages and methods for the treatment of cancer
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
KR20150123804A (ko) 향상된 안정성을 갖는 척수강내 히드로모르폰 용액
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
JP6382231B2 (ja) 神経保護剤としてのホスファプラチン
WO2008124823A1 (en) Method of treating melanoma
EP3651754A1 (de) Propion- und/oder buttersäure zur verwendung zur prophylaktischen und/oder unterstützenden therapeutischen behandlung von morbus parkinson
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
EP3265089B1 (en) New use of the isoquinoline derivative salsolinol for diabetic wound healing
US20170273938A1 (en) Use of flavonoids in manufacturing compositions for wound healing
CN107879961A (zh) 一种治疗肝纤维化的组合物
KR101710244B1 (ko) 히드로모르폰 히드로클로라이드 용액의 개선된 안정성
JP6840178B2 (ja) ヒドロキシアニゴルホンの使用
MX2022004954A (es) Composiciones farmaceuticas que contienen diacido de oligosacarido de alginato.
US20160030502A1 (en) Eye Health Supplement
JP2024536181A (ja) 神経変性眼疾患を治療するためのプリドピジン及びその類似体
NZ733953A (en) Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2024 BY ENVOY

Effective date: 20230530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2025 BY ENVOY

Effective date: 20240604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2026 BY ACUMASS

Effective date: 20250526